Biontech

Developer of immunotherapeutics for the treatment of cancer and other diseases

placeMainz, Rhineland-Palatinate, Germany calendar_todayFounded 2008 groups4,530 employees language biontech.com

Registered entities

Web presence

Audience by country — top 5 markets by share of visits.

CountryShare
Germany39.8%
United States21.8%
United Kingdom19.9%
India2.1%
Australia2%

Social engagement

Social engagement: 299.1K social following, 2 posts in the last 12 months — below the industry typical range.

Investor mix

30 investors on record; lead investors include Redmile Group, Fidelity Investments, Pfizer Venture Investments, MIG Fonds.

Investor typeCountShare
Venture capital1343%
Private equity413%
Bank & private debt13%
Other / undisclosed1240%

Share of voice

Share of voice in Germany: 99.2% of web traffic across its competitive set; worldwide: 36.5%.

Recent activity

15 Jun 2026
Partnership
Victorian Government agency mRNA Victoria
24 Mar 2026
Event
European Lung Cancer Congress (ELCC2026)
Coming soon